Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
The Leukemia & Lymphoma Society (LLS) today announced it has committed $28.6 million in new research investment to advance the most promising blood cancer science at leading academic and medical institutions around the world, including Dana-Farber Cancer Institute, Weill Cornell Medical College and MD Anderson Cancer Center. As LLS leads the charge to find cures for cancer patients, this new funding, along with ongoing investment in LLS’s aggressive research agenda, brings LLS’s total commitment to blood cancer research to more than $1 billion. The investment has led to the development of nearly every therapy currently used to treat the blood cancers.
Along with these new research grants, LLS remains committed to collaborating with biotechnology companies through its innovative Therapy Acceleration Program® (TAP), a model pioneered by LLS in the cancer arena in recognition that traditional research approaches weren’t yielding treatments and cures fast enough for patients. LLS commits approximately $13 million a year to its TAP initiatives. As part of the 24 current such collaborations, LLS recently initiated new investments with Kite Pharma and OncoPep.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554852-lls-cancer-research-funding/
Executive Education at LUISS Business School is an experience aimed at inspiring people to develop hard and soft skills, innovative mind-set, entrepreneurship attitude and multi-ethnic interactions. “It is no longer about offering learning to enhance someone’s long term career – says Professor Paolo Boccardelli, the Dean – it is about creating direct impact in support of change. We intend to boost our student professional and personal growth while promoting corporate sustainability and social responsibility”.
LUISS Business School is the School of Business and Management of University LUISS Guido Carli, in Rome (Italy), which leads the development and the growth of individuals and companies. Through the Competence Centres & Labs, which are centres of Business Practice and Research, the School is full embedded in the innovation of the training programmes even thanks to the cooperation with Key Corporate Partners and an International Facultyin order to offer a real change to those who live the experience at LUISS BS.
Its reputation is based on strong values: openness in all the main issues; responsibility, because of its strong commitment with ethically and socially responsible issues; independence, in order to keep safe a very challenging environment.
To view the multimedia release please
http://www.multivu.com/players/English/7588251-luiss-bs-executive-education-italy/
ATLANTA (January 29, 2019) – Leading early education and care provider Primrose Schools and its nearly 400 independently owned schools across the country joined forces for the most successful fundraising and volunteering year in the company's 36-year history. Through its Primrose PromiseSM CSR program, more than 63,000 Primrose children and their families engaged in giving efforts that generated more than $914,000 for local and national charities in 2018. These efforts represent a 16.8 percent increase over the company's 2017 impact.
Primrose Promise gives Primrose team members, children and their families meaningful opportunities to make a difference in their communities. Primrose Promise efforts focus on three key impact areas – people, the planet and philanthropy – and help Primrose fulfill its mission to forge a path that leads to a brighter future for all children.
To view the multimedia release go to:
https://www.multivu.com/players/English/8257755-primrose-schools-fundraising-record-csr/
Today Safe Kids Worldwide released a new research report that found kids are getting into medicine at an alarming rate. Every minute of every day, a poison control center receives a call about a potential medicine poisoning for a child age five and under. And 67,000 times each year, or every eight minutes, a young child goes to the emergency room for medicine poisoning. This is a 30 percent increase over the past ten years.
In its report entitled An In-Depth Look at Keeping Young Children Safe Around Medicine, Safe Kids examines data from the U.S. Consumer Product Safety Commission, information from poison control centers and findings from several focus groups among moms. The report reviews what is happening in households that leads to these disturbing numbers and offers parents simple things they can do to protect their children.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60845-safe-kids-worldwide-keeping-young-children-safe-around-medicine
Primrose Schools®, a national high-quality early education and care provider, raised more than $773,000 for local and national children’s charities in 2017, breaking its previous record by more than $53,000. More than 350 Primrose preschools across the U.S. contributed to this effort, demonstrating the company’s mission to forge a path that leads to a brighter future for all children.
Last year, more than 55,000 preschool children and their families – in addition to Primrose National Leadership Support Team members, Franchise Owners, teachers and staff – participated in a variety of fundraising efforts throughout the year. These initiatives are part of the company’s Primrose PromiseSM corporate social responsibility program, which was founded in 2014 and represents the company’s commitment to make a difference in the lives of all children, especially those at greatest risk.
To view the multimedia release go to:
https://www.multivu.com/players/English/8014458-primrose-childrens-charity-fundraising-donations/
China’s leading robotics developer and manufacturer HIT Robot Group (HRG) launches a state-of-the-art configurable and flexible automatic production line for high-precision jade processing. This intelligent production line exemplifies a revolutionary transformation in design concept from “centralized control” to “enhanced decentralized control”, which leads to scalable customization, greater flexibility for users, and therefore rapid response to market.
HRG has channeled its expertise in intelligent processing management into the new production line to achieve productivity and flexibility. “By uploading real-time data to the Internet, the production line can map its capability with dynamic product requests, and therefore making fast adjustment to market changes and accordingly allocating idle resources,” said Zhu Lei, HRG’s vice president.
To view the multimedia release go to:
http://www.multivu.com/players/English/8014051-hit-robot-group-jade-production-line/
Losing weight and being healthier are at the top of everyone’s New Year’s resolutions. But, despite the best intentions, work, kids, and social events often push lifestyle changes to the bottom of the list. While many are familiar with type 2 diabetes, fewer are aware of prediabetes, a serious health condition that affects 86 million Americans (more than 1 in 3) and often leads to type 2 diabetes. People with prediabetes have higher than normal blood glucose (sugar) levels, but not high enough yet to be diagnosed with type 2 diabetes.
To raise awareness and help people with prediabetes know where they stand and how to prevent type 2 diabetes, the American Diabetes Association (ADA), the American Medical Association (AMA), and the Centers for Disease Control and Prevention (CDC) have partnered with the Ad Council to launch the first national public service advertising (PSA) campaign about prediabetes. The PSA campaign, featuring first-of-its-kind communications techniques, was developed pro bono by Ogilvy & Mather New York for the Ad Council.
Nearly 90 percent of people with prediabetes don’t know they have it and aren’t aware of the long-term risks to their health, including type 2 diabetes, heart attack, and stroke. Current trends suggest that, if not treated, 15 to 30 percent of people with prediabetes will develop type 2 diabetes within five years. The good news is that prediabetes often can be reversed through weight loss, diet changes and increased physical activity. Diagnosis is key: research shows that once people are aware of their condition, they are much more likely to make the necessary lifestyle changes.
To view the multimedia release go to:
http://www.multivu.com/players/English/7731551-ad-council-prediabetes-psa/
Based on the groundbreaking HBO® series, GAME OF THRONES: The Touring Exhibition will give fans the experience of a lifetime with an up-close and personal look into the world of Westeros and Essos. In collaboration with HBO Global Licensing, global events provider GES designed and built the show’s largest public display to date. The exhibition beautifully showcases the sumptuous costumes, authentic props, and majestic settings from all seven seasons of the worldwide hit series GAME OF THRONES in an interactive, immersive experience which leads visitors through several dynamically themed exhibition areas. Sold Out and Encore are partnering with GES to present the exhibition in Barcelona.
GAME OF THRONES actors Tom Wlaschiha, who played Faceless Man Jaqen H'ghar, and Ian Beattie, who played Kingsguard Knight Meryn Trant, were on hand to celebrate the grand opening.
“It is an incredible honor to join my co-star at the opening of GAME OF THRONES: The Touring Exhibition in Barcelona. It has been a trip down memory lane to see all of the props and costumes again. I highly recommend it to fans and newcomers alike,” said Ian Beattie.
To view the multimedia release go to:
https://www.multivu.com/players/English/8194651-game-of-thrones-touring-exhibition-barcelona/
